Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

Provided By Globe Newswire

Last update: Apr 1, 2022

SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”).